Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
Welcome to Amarin Corporation's conference call to discuss its second quarter 2022 financial results and operational update. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act.
Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.